News

 

 

Article in New York Times: Start-Up Raises $200 Million to Speed Up Drug Trials

 

Press Release: Paradigm Launches with $203 Million to Rebuild the Clinical Research Ecosystem

 

Fireside Chat: CEO Kent Thoelke and Mubadala Executive Director Alaa Halawa